ASCO 2022
American Society of Clinical Oncology
June 3-7, 2022
This year's meeting will be in-person in Chicago or online attendance.
The American Society of Clinical Oncology (ASCO) annual meeting offers premier scientific events for oncology professionals, patient advocates, industry representatives and major media outlets worldwide.
The 2022 ASCO annual meeting, held in Chicago, provides an opportunity to learn about the latest developments in cancer science from Fred Hutchinson Cancer Center and research institutions around the world. The program features more than 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.
Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance have merged to form Fred Hutchinson Cancer Center, a unified adult cancer research and care center that brings together SCCA and Fred Hutchinson Cancer Research Center into a single, independent, nonprofit organization that is also a clinically integrated part of UW Medicine and UW Medicine’s cancer program.
Featured Presentations
Joe Unger, Ph.D.
Oral Presentation: Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials
Monday, June 6, 2:24 p.m. PDT
In 2017, a joint research statement was issued recommending that certain eligibility criteria in cancer clinical trials, including those related to brain metastases, be broadened to make trials more inclusive. Unger and colleagues found that these recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. To the researchers' knowledge, this is the first evidence that cancer clinical trials have become more inclusive of a broader set of patients in response to these recommendations. More inclusive eligibility improves trial access and representativeness, increasing trial validity and the pace at which trials enroll.
Read more about cancer clinical trial inclusion on Hutch News: Cancer clinical trials exclude too many patients: That’s changing
Highlights of Fred Hutch Presentations at ASCO
Clinical Trials | Health Care Systems and Value | Cancer Immunology and Immunotherapy | Cancer Survivorship | Biomarkers
Poster Discussion: Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor|
Presenter: Dr. Lee Cranmer
Sunday, June 5, 9:30 a.m.
Poster: Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers
Presenter: Dr. Ryan Lynch
Sunday, June 5, 6 a.m.
Poster: Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas
Presenter: Dr. Ryan Lynch
Saturday, June 4, 6 a.m.
Poster: ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade
Presenter: Dr. Joshua Veatch
Monday, June 6, 11:15 a.m.
Poster Discussion: A pragmatic cluster-randomized trial of a computerized clinical decision support system to improve colony stimulating factor prescribing for patients with cancer receiving myelosuppressive chemotherapy (SWOG S1415CD)
Presenter: Dr. Scott Ramsey (Conducted through the SWOG Cancer Research Network)
Saturday, June 4, 11:15 a.m. PDT
Oral: Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer
Presenter: Dr. Hiba Khan
Monday, June 6, 6:12 a.m. PDT
Poster: Cost effectiveness of reduced intensity conditioning and transplantation of unrelated umbilical cord blood versus HLA haploidentical related bone marrow for adults with hematologic malignancies
Presenter: Dr. Lotte Steuten
Monday, June 6, 2022, 1:15 p.m.
Poster: Evaluating the feasibility of using an electronic patient-reported outcome (ePRO) smartphone application (app) and biosensor by patients with cancer undergoing systemic treatments
Presenter: Dr. Karma Kreizenbeck
Saturday, June 4, 2022, 1:15 p.m.
Poster: Assessing health electronically for adolescent and young adult oncology patients (AHEAD Study)
Presenter: Dr. Tyler Ketterl
Saturday, June 4, 11:15 a.m.
Oral Discussion: Rare and vulnerable patient populations in skin cancer: A work in progress
Presenter: Dr. Shailender Bhatia
Sunday, June 5, 10:21 a.m.
Oral Presentation: The Medicaid expansion of the Affordable Care Act and participation of patients with Medicaid in cancer clinical trials
Presenter: Dr. Joe Unger (Conducted through the SWOG Cancer Research Network)
Poster: Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma
Presenter: Dr. Lisa May Ling Tachiki
Sunday, June 5, 6 a.m.
Poster: Merkel polyoma virus specific T cell receptor transgenic T cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma
Presenter: Dr. Joshua Veatch
Sunday, June 5, 6 a.m.
Poster: The relationship between chronic health conditions and employment transitions among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
Presenter: Dr. Neel Bhatt
Monday, June 6, 6 a.m.
Poster: LVEF decline in relation to body composition among women treated for breast cancer: WF-97415
Presenter: Dr. Kerryn Reding
Monday, June 6, 11:15 a.m.
Poster: Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)
Presenter: Dr. Petros Grivas
Monday, June 6, 11:15 a.m.
